Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forma Therapeutics Inc.

http://www.formatherapeutics.com

Latest From Forma Therapeutics Inc.

Novo Nordisk Committed To Advancing In Cardiovascular

The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.

Cardiovascular Business Strategies

Zealand Nabs Novo Nordisk To Save Zegalogue Launch

US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.

Metabolic Disorders Deals

Novo Nordisk’s Forma Buy Builds On Foothold In Rare Blood Disorders

Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.

M & A Deals

Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine

Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register